Clinical Trial: Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

This study is no longer recruiting patients.

Sponsors and Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Child Health and Human Development (NICHD)
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)


The purpose of this study is to determine if 2 doses of Pneumococcal Conjugate Vaccine (PCV) followed by 1 dose of Pneumococcal Polysaccharide Vaccine (PPV) in HIV-infected children on anti-HIV therapy is helpful and safe in fighting pneumococcal infections in this group of children. This study will also look at the protection provided by childhood vaccination against measles, pertussis, and hepatitis B virus. Pneumococcal infections are the most common AIDS-related infection in HIV-infected children. PCV may help reduce the chances of HIV-infected children getting pneumococcal infections. This study will look at whether pneumococcal vaccines are safe and effective in HIV-infected children receiving HAART. It will look at whether HIV-infected children are protected by childhood vaccines received previously and if more doses are safe and improve protection.

Condition Treatment or Intervention
HIV Infections
Hepatitis B
Pneumococcal Infections
 Vaccine: Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed
 Vaccine: Measles-Mumps-Rubella Vaccine (Live)
 Vaccine: Pneumococcal Vaccine, Polyvalent (23-valent)
 Vaccine: Pneumococcal Conjugate Vaccine, Heptavalent
 Vaccine: Hepatitis B Vaccine (Recombinant)

MedlinePlus related topics:  AIDS;   Bacterial Infections;   Bronchitis;   Hepatitis B;   Measles;   Respiratory Diseases;   Streptococcal Infections;   Throat Disorders

Study Type: Interventional
Study Design: Prevention

Official Title: Evaluation of the Immunogenicity of Pneumococcal Conjugate Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Treated with Highly Active Antiretroviral Therapy (HAART)

Further Study Details: 

Expected Total Enrollment:  300

Infection by Streptococcus pneumoniae is the most frequent opportunistic infection observed in HIV-infected children. PCVs are immunogenic and efficacious in normal children and offer hope of reducing pneumococcal infections in HIV-infected children. The degree to which children on HAART are protected by prior immunizations and are responsive to new immunizations is still largely undefined. This study is designed to answer whether PCV immunizations are safe and effective. The immune responses to prior immunizations and responsiveness to booster doses of vaccines against measles, pertussis, and hepatitis B virus of children on HAART will also be examined. Answers to these questions will determine whether these children are likely to be protected against these clinically relevant pathogens and whether they should routinely receive booster doses of these vaccines after a period of HAART.

Patients are stratified on the basis of CD4 percentage and age. Patients that previously received a primary hepatitis B vaccine (HBV) series receive an HBV immunization at entry. Other vaccinations may be given (based on age and/or CD4 cell measurement, and immunization status) for PCV at entry and 2 months, and measles-mumps-rubella (MMR) vaccine and PPV at 4 months. Some patients may be administered DTaP at a 6-month visit on the basis of age, previous immunization history, and negative tetanus antibody status. Follow-up visits are done at 8, 12, and 24 months. Blood samples are collected at all clinic visits for assessment of HIV RNA, immune responses against pneumococcus, measles, pertussis, and hepatitis B virus, as well as for laboratory evaluations.


Ages Eligible for Study:  2 Years   -   18 Years,  Genders Eligible for Study:  Both


Inclusion Criteria

Patients may be eligible for this study if they:

  • Are 2 to 18 years of age.
  • Are HIV-infected.
  • Have a viral load (amount of HIV in the blood) under 60,000 copies/ml within 30 days of study entry.
  • Have been on their current anti-HIV drugs for at least 3 months.
  • Have received 4 or more doses of a pertussis vaccine.
  • Have received 1 or more doses of measles vaccine unless a CD4 percent or CD4 number ruled out taking the vaccine. (This reflects a change in the CD4 requirement.)
  • Expect to be able to complete all study injections and follow-up.
  • Have a negative pregnancy test if able to have children and use effective methods of birth control.
  • Have parent or guardian's consent if under 18 years of age.
  • Have received an approved hepatitis B vaccine series. Not required for study entry, but children who have received this vaccine will be studied.
  • (This study was changed to allow patients who became HIV infected after birth, have a viral load between 30,000 and 60,000 copies/ml, and who have been on their current anti-HIV drugs for 3 to 6 months.)

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Had a certain CD4 level before beginning anti-HIV drugs and at screening.
  • Have received any killed vaccine within 4 weeks, or any live vaccine within 6 weeks, of entering the study.
  • Have received pneumococcal vaccines or had a reaction to PPV.
  • Have had an allergic reaction to any measles or hepatitis B vaccines, or to other routine childhood immunizations if 13 years of age or less.
  • Have any other condition that would make receiving study vaccines inadvisable.
  • Are currently on medications that affect the immune system, except for G-CSF and erythropoietin. This includes the equivalent to more than 1 mg/kg/day of prednisone in the 2 weeks preceding study screening. Nonsteroidal anti-inflammatory agents and inhaled corticosteroids are not excluded.
  • Have received certain blood products within the previous 6 months.
  • Have other diseases of the immune system.
  • Have had cancer within 3 months of study screening or are being treated or have been treated for cancer within 3 months of study entry.
  • Are pregnant.
  • Have any other disease or previous surgery that would interfere with study treatment.
  • Are likely to have bleeding disorders.
  • Show certain side effects to vaccines at screening.

Location Information

      Univ of Alabama at Birmingham - Pediatric, Birmingham,  Alabama,  35233,  United States

      UCSF / Moffitt Hosp - Pediatric, San Francisco,  California,  941430105,  United States

      Children's Hosp of Oakland, Oakland,  California,  946091809,  United States

      Long Beach Memorial (Pediatric), Long Beach,  California,  90801,  United States

      Los Angeles County - USC Med Ctr, Los Angeles,  California,  90033,  United States

      Univ of California, San Diego, San Diego,  California,  92103,  United States

      Harbor UCLA Med Ctr, Huntington Beach,  California,  92646,  United States

      Children's Hosp of Denver, Denver,  Colorado,  802181088,  United States

      Yale Univ Med School, New Haven,  Connecticut,  06504,  United States

      Connecticut Children's Med Ctr, Farmington,  Connecticut,  060303805,  United States

      Univ of Miami (Pediatric), Miami,  Florida,  33161,  United States

      Univ of Florida Health Science Ctr / Pediatrics, Jacksonville,  Florida,  32209,  United States

      Univ of Florida Gainesville, Gainesville,  Florida,  32610,  United States

      Emory Univ Hosp / Pediatrics, Atlanta,  Georgia,  30306,  United States

      The Med Ctr Inc, Columbus,  Georgia,  31901,  United States

      Chicago Children's Memorial Hosp, Chicago,  Illinois,  606143394,  United States

      Cook County Hosp, Chicago,  Illinois,  60612,  United States

      Univ of Chicago Children's Hosp, Chicago,  Illinois,  606371470,  United States

      Tulane Univ / Charity Hosp of New Orleans, New Orleans,  Louisiana,  701122699,  United States

      Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore,  Maryland,  21201,  United States

      Johns Hopkins Hosp - Pediatric, Baltimore,  Maryland,  212874933,  United States

      Children's Hosp of Boston, Boston,  Massachusetts,  021155724,  United States

      Boston City Hosp / Pediatrics, Boston,  Massachusetts,  02118,  United States

      Baystate Med Ctr of Springfield, Springfield,  Massachusetts,  01199,  United States

      Univ of Massachusetts Med School, Worcester,  Massachusetts,  016550001,  United States

New Jersey
      Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark,  New Jersey,  071032714,  United States

      St Joseph's Hosp & Med Center, Paterson,  New Jersey,  07503,  United States

New York
      Harlem Hosp Ctr, New York,  New York,  10037,  United States

      SUNY - Brooklyn, Brooklyn,  New York,  11203,  United States

      Schneider Children's Hosp, New Hyde Park,  New York,  11040,  United States

      Bellevue Hosp / New York Univ Med Ctr, New York,  New York,  10016,  United States

      Columbia Presbyterian Med Ctr, New York,  New York,  10032,  United States

      Bronx Lebanon Hosp Ctr, Bronx,  New York,  10457,  United States

      State Univ of New York at Stony Brook, Stony Brook,  New York,  117948111,  United States

      Univ of Rochester Med Ctr, Rochester,  New York,  146420001,  United States

      Montefiore Medical / AECOM, Bronx,  New York,  19461,  United States

      Columbus Children's Hosp, Columbus,  Ohio,  432052696,  United States

South Carolina
      Med Univ of South Carolina, Charleston,  South Carolina,  294253312,  United States

      Saint Jude Children's Research Hosp of Memphis, Memphis,  Tennessee,  381052794,  United States

      Texas Children's Hosp / Baylor Univ, Houston,  Texas,  77030,  United States

      Med College of Virginia, Richmond,  Virginia,  23219,  United States

Puerto Rico
      Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan,  009365067,  Puerto Rico

      Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon,  00956,  Puerto Rico

Study chairs or principal investigators

Mark Abzug,  Study Chair

More Information

Haga clic aquí para ver información sobre este ensayo clínico en español.

Study ID Numbers:  ACTG P1024; PACTG 1024
Record last reviewed:  August 2004
Last Updated:  April 7, 2005
Record first received:  March 31, 2001 Identifier:  NCT00013871
Health Authority: United States: Food and Drug Administration processed this record on 2005-04-08

Cache Date: April 9, 2005